| Literature DB >> 29061136 |
Umar Farooq1, Sadia Naz2, Binte Zehra3, Ajmal Khan4, Syed Abid Ali5, Ayaz Ahmed6, Rizwana Sarwar2, Syed Majid Bukhari2, Abdur Rauf7, Izhar Ahmad8, Yahia Nasser Mabkhot9.
Abstract
BACKGROUND: The emergence of chemoresistant cancers and toxicity related to existing chemotherapeutic agents, demand the search for new pharmacophore with enhanced anti-cancer activity and least toxicity. For this purpose, three new sesquiterpenes were isolated from ethyl acetate fraction of the aerial parts of the plant Polygonum barbatum and evaluated for their anti-cancer potential.Entities:
Keywords: Angiogenesis; Apoptosis; Cox-2; Non-small cell lung carcinoma; Polygonum Barbatum; Sesquiterpenes; VEGF
Mesh:
Substances:
Year: 2017 PMID: 29061136 PMCID: PMC5654143 DOI: 10.1186/s12885-017-3667-9
Source DB: PubMed Journal: BMC Cancer ISSN: 1471-2407 Impact factor: 4.430
1H NMR (500 MHz, CDCl3), δH in ppm
| Compound 1 | Compound 2 | Compound 3 | |
|---|---|---|---|
| Carbon No |
1H–NMR |
1H–NMR |
1H–NMR |
| 1 | – | – | – |
| 2 | – | – | – |
| 3 | 6.80, s | 6.83, s | 6.75, s |
| 4 | – | – | – |
| 5 | – | – | – |
| 6 | 7.22 (d, | 7.20 (d, | 7.22 (d, |
| 7 | 7.46 (d, | 7.28 (d, | 7.48 (d, |
| 8 | – | – | – |
| 9 | – | – | – |
| 10 | 6.51, (d, | 6.48, (d, | 6.50, (d, |
| 11 | 3.20, m | 3.20, m | 3.18, m |
| 12 | 1.26, (d, | 1.28, (d, | 1.29, (d, |
| 13 | 1.26, (d, | 1.28, (d, | 1.29, (d, |
| 14 | – | – | – |
| 15 | 4.99, s | – | – |
| 16 | – | 2.40, s | 2.43, s |
| 9-OCH3 | 3.90, s | 3.88, s | 3.80, s |
| 14-OCH3 | – | – | 3.87, s |
13C NMR (125 MHz, CDCl3), δC in ppm
| Compound | Compound | Compound | |
|---|---|---|---|
| Carbon No |
13C–NMR |
13C–NMR |
13C–NMR |
| 1 | 123.9 | 123.2 | 125.3 |
| 2 | 138.1 | 140.4 | 140.7 |
| 3 | 132.3 | 130.7 | 122.6 |
| 4 | 140.1 | 138.8 | 134.7 |
| 5 | 139.6 | 137.7 | 138.4 |
| 6 | 119.7 | 120.1 | 120.1 |
| 7 | 133.4 | 125.4 | 128.1 |
| 8 | 129.7 | 144.7 | 146.7 |
| 9 | 158.5 | 160.1 | 159.6 |
| 10 | 143.2 | 141.4 | 142.1 |
| 11 | 32.9 | 32.4 | 32.1 |
| 12 | 27.6 | 28.3 | 25.4 |
| 13 | 27.6 | 28.3 | 25.4 |
| 14 | 179.8 | 180.7 | 175.1 |
| 15 | 62.4 | 174.1 | 172.6 |
| 16 | – | 23.4 | 22.7 |
| 9-OCH3 | 58.7 | 60.4 | 59.6 |
| 14-OCH3 | – | – | 57.6 |
Fig. 1Important HMBC (→) correlations of compound 1–3
50% inhibitory concentration of compound 1–3 against various cell lines. The compound 3 showed potent anti-cancer activity against NSCLC cells as compared to cisplatin (standard drug)
| NCI-H460 | MCF-7 | HeLa | NIH-3 T3 | |
|---|---|---|---|---|
| Compound 1 | 0.23 mM ± 0.85 | Inactive | Inactive | 0.42 mM ± 0.13 |
| Compound 2 | 0.13 mM ± 0.38 | Inactive | Inactive | 0.28 mM ± 0.5 |
| Compound 3 | 17.86 μM ± 0.72 | 11.86 μM ± 0.46 | 32.13 μM ± 0.6 | 30.32 μM ± 0.93 |
| Cisplatin | 19 μM ± 1.24 | 09.62 μM ± 0.5 | 16.19 μM ± 0.7 | – |
Fig. 2Phase contrast microscopic images of NCI-H460 cells after treatment with compound 3 at 20 and 40 μM concentrations. In control well, the cells were in their normal morphology while treated cells died and escaped the monolayer after 24 h of the treatment. The images were taken at 10X magnification
Fig. 3Phase contrast microscopic images of normal NIH-3 T3 cells after treatment with compound 3 at 20 and 40 μM concentrations at different time intervals. Control well showed cells in their normal morphology while both live and dead populations were found in treated wells after 48 h. The images were taken at 10X magnification
Fig. 4a The apoptotic potential of compound 3 in lung cancer NCI-H460 cells. FACS images showed percent apoptotic cells after treatment with compound 3. Cells were significantly undergoing apoptosis as compared to the vehicle control. b Graphical representation of the cell population in each phase of apoptosis and expressed as the mean of three independent experiments. *** p < 0.001 as compared to control
Fig. 5a Gene expression analysis of pro-apoptotic (BAK and BAX) and anti-apoptotic genes (BCL-2 L1 and p53) after 48 h treatment of NCI-H460 cells with compound 3. GAPDH was used as a control housekeeping gene. b Quantitative analysis of the expression by calculating fold change in integrated density treated versus control genes. *** p < 0.001 and ** p < 0.01 when compared to the control
Fig. 6a Anti-migration potential of compound 3 at 20 and 40 μM concentrations against lung cancer NCI-H460 cells. The control cells healed 33% and 52% scratch after 24 h and 48 h whereas 17% and 24% healing was observed at 40 μM of compound 3. b Graphical representation of the rates of migration in control and treated wells. ** p < 0.01 and * p < 0.05 control vs treated
Fig. 7a Gene expression of angiogenic VEGF and COX-2 genes after the treatment of NCI-H460 cells. b Graphical representation of quantitative analysis of the gene expression. *** p < 0.001 as compared to the control
Fig. 8Structures of compound 1–3
Primer sequences and annealing temperatures of genes used in this study
| Gene | Sequence | Annealing Temperature | References |
|---|---|---|---|
| BCL-2 L1 | R: ATGGTCAGTGTCTGGTCATT | 57 | [ |
| p53 | R: CTCTCGGAACATCTCGAAGCG | 57 | [ |
| BAX | R: GGCCCCAGTTGAAGTTGC | 54 | [ |
| BAK | R: CCTGAGAGTCCAACTGCAAA | 60 | [ |
| VEGF | R: ACCGCCTCGGCTTGTCAC | 54 | [ |
| COX-2 | R: CGCTCAGCCATACAGCAAATCCTT | 56 | [ |
| GAPDH | R: GGTCTACATGGCAACTGTGA | 59 | [ |